Across TCGA pan-cancer cohorts, BCL2L15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BCL2L15 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BCL2L15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BCL2L15 expression acts as an unfavorable survival marker.

BLCA and SKCM are the cancer types where BCL2L15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.183	0.720	.001	21	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: BCL2L15 tumor-vs-normal RNA expression · all BCL2L15 data types